Skip to main content
Clinical Trials/EUCTR2005-001656-21-HU
EUCTR2005-001656-21-HU
Active, not recruiting
Not Applicable

A randomized, multi-center, double-blind, parallel-group, multiple-dose study assessing the analgesic efficacy and safety of 3 different doses of GRT0151Y compared to placebo and an active comparator in adults following tonsillectomy

Grünenthal GmbH0 sites450 target enrollmentJune 15, 2005

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Not specified
Sponsor
Grünenthal GmbH
Enrollment
450
Status
Active, not recruiting
Last Updated
14 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
June 15, 2005
End Date
TBD
Last Updated
14 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • 1\. Male or female subjects aged 18 65 years inclusive at enrolment and study entry
  • 2\. ASA classification I\-II
  • 3\. Planned bilateral tonsillectomy due to recurrent acute tonsillitis or chronic tonsillitis
  • 4\. Anesthesiological and surgical procedures performed according to the protocol
  • 5\. Moderate to severe postoperative pain at rest on 4 point VRS and a pain intensity at rest of minimum 4 on 11 point\-NRS within 4 hours following the end of the anesthesia
  • 6\. Negative urine abuse test at the enrolment visit and pre operative examination. Subjects who declare that they are receiving benzodiazepines for medical purposes may participate even if they test positive.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1\.2 Adults (18\-64 years) yes
  • F.1\.2\.1 Number of subjects for this age range

Exclusion Criteria

  • 1\. Pregnancy or breastfeeding mother
  • 2\. Evidence or history of neurotic personality, psychiatric illness, epilepsy or suicide risk
  • 3\. Women of childbearing potential who does not use satisfactory contraception (i.e. double barrier, hormonal or IUD method) 28 days prior to enrolment visit, during the study and until 28 days after the follow\-up visit.)
  • 4\. History of chronic hepatitis B or C, or HIV, or presence of active hepatitis B or C within the post 3 months. History of AIDS
  • 5\. Poor medical status (e.g. NYHA class \= 3; child classification for hepatic impairment \>A (Pugh et al., 1973\); decompensated chronic obstructive pulmonary disease) or, at the discretion of the investigator, clinical signs that raise concerns about subject’s suitability for the study
  • 6\. Creatinine higher than 1\.5X upper limit of normal range
  • 7\. ALT and/or AST higher than 3X upper limit of normal range
  • 8\. At enrolment ECG with findings which could impact operability or any planned study procedure: e.g. marked repolarization abnormality (e.g. suspicious or definite congenital long QT syndrome) and/or QT values of: QTCB females \= 450 msec, QTCB males \= 430 msec, uncorrected QT \= 500 msec
  • pre\-operative ECG with findings which could impact operability or any planned study procedure
  • 9\. Known contraindications/hypersensitivity to the comparator tramadol and rescue medication acetaminophen or diclofenac

Outcomes

Primary Outcomes

Not specified

Similar Trials